Coave Therapeutics
Gaelle M. Lefevre has an extensive background in research and project management within various organizations related to genetics, molecular biology, and ocular diseases. Gaelle M. holds a PhD in Life Sciences and has conducted research on topics such as gene expression regulation in obesity and diabetes, epigenetic factors in kidney function, and inner ear hair bundle development in Usher syndrome. With experience in marketing and business development, Gaelle has also worked on promoting innovative tools for weight loss tracking. Currently serving as the VP at Coave Therapeutics, Gaelle specializes in portfolio strategy, target discovery, and translational ophthalmology.
This person is not in any teams
Coave Therapeutics
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.